Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen

Breast Cancer Research and Treatment

Volumn 126, Issue 2, 2011, Pages 421-430

  Khoshnoud, Mahmoud R ^a   Löfdahl, Britta ^b   Fohlin, Helena ^c   Fornander, Tommy ^a   Stål, Olle ^d   Skoog, Lambert ^a   Bergh, Jonas ^e,f   Bo, Nordenskjöld ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Breast cancer; Cytosol; Estrogen receptor; Immunohistochemical; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ACCURACY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOSOL; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LONG TERM CARE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; RECEPTORS, ESTROGEN; ROC CURVE; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 79958752360     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1202-7     Document Type: Article

References (35)

1. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21(17):3357-3365 (Pubitemid 46606270)
2. McGuire WL (1980) An update on estrogen and progesterone receptors in prognosis for primary and advanced breast cancer. In: Iacobelli S et al (eds) Hormones and cancer. Raven Press, New York
3. Group EBCTC (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451-1467
4. Crowe JP Jr, Gordon NH, Hubay CA, Shenk RR, Zollinger RM, Brumberg DJ, McGuire WL, Shuck JM (1991) Estrogen receptor determination and long term survival of patients with carcinoma of the breast. Surg Gynecol Obstet 173(4):273-278
5. Maynard PV, Blamey RW, Elston CW, Haybittle JL, Griffiths K (1978) Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res 38(11 Pt 2):4292-4295 (Pubitemid 9054220)
6. Knight WA, Livingston RB, Gregory EJ, McGuire WL (1977) Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37(12):4669-4671 (Pubitemid 8239679)
7. Aamdal S, Bormer O, Jorgensen O, Host H, Eliassen G, Kaalhus O, Pihl A (1984) Estrogen receptors and long-term prognosis in breast cancer. Cancer 53(11):2525-2529 (Pubitemid 14102497)
8. Donegan WL (1992) Prognostic factors. Stage and receptor status in breast cancer. Cancer 70(6 Suppl):1755-1764
9. Early Breast Cancer Trialist's Collaborative Group (2005) Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-years survival: an overview of the randomised trials. Lancet 365:1687-1717
10. Khoshnoud MR, Fornander T, Johansson H, Rutqvist LE (2008) Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen. Breast Cancer Res Treat 107(1):71-78 (Pubitemid 350179581)
11. Pertschuk LP, Kim DS, Nayer K, Feldman JG, Eisenberg KB, Carter AC, Rong ZT, Thelmo WL, Fleisher J, Greene GL (1990) Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer 66(8):1663-1670 (Pubitemid 20381196)
12. Stierer M, Rosen H, Weber R, Hanak H, Auerbach L, Spona J, Tuchler H (1998) Comparison of immunohistochemical and biochemical measurement of steroid receptors in primary breast cancer: evaluation of discordant findings. Breast Cancer Res Treat 50(2):125-134 (Pubitemid 28454391)
13. Zafrani B, Aubriot MH, Mouret E, De Cremoux P, De Rycke Y, Nicolas A, Boudou E, Vincent-Salomon A, Magdelenat H, Sastre-Garau X (2000) High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology 37(6):536-545 (Pubitemid 32099165)
14. Chebil G, Bendahl PO, Idvall I, Ferno M (2003) Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer - clinical associations and reasons for discrepancies. Acta Oncol 42(7):719-725 (Pubitemid 37445291)
15. Beck T, Weikel W, Brumm C, Wilkens C, Pollow K, Knapstein PG (1994) Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC). Gynecol Oncol 53(2):220-227 (Pubitemid 24177048)
16. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Corgnati A, Sperotto L, Recaldin E, Spagnolli P, Manfrin E et al (1997) Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 45(3):241-249 (Pubitemid 27453793)
17. Fisher ER, Anderson S, Dean S, Dabbs D, Fisher B, Siderits R, Pritchard J, Pereira T, Geyer C, Wolmark N (2005) Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer 103(1):164-173 (Pubitemid 39665470)
18. Alberts SR, Ingle JN, Roche PR, Cha SS, Wold LE, Farr GH Jr, Krook JE, Wieand HS (1996) Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer 78(4):764-772 (Pubitemid 26268606)
19. Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurkula M, Langman G, Mazzucchelli L et al (2006) Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 98(21):1571-1581 (Pubitemid 44680908)
20. Rutqvist LE, Cedermark B, Glas U, Johansson H, Nordenskjold B, Skoog L, Somell A, Theve T, Friberg S, Askergren J (1987) The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat 10(3):255-266 (Pubitemid 18036272)
21. Wrange O, Nordenskjold B, Silfversward C, Granberg PO, Gustafsson JA (1976) Isoelectric focusing of estradiol receptor protein from human mammary carcinoma - a comparison to sucrose gradient analysis. Eur J Cancer 12(9):695-700
22. Wrange O, Nordenskjold B, Gustafsson JA (1978) Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel. Anal Biochem 85(2):461-475 (Pubitemid 9059206)
23. Ferno M, Borg A, Norgren A (1983) A comparison of two steroid receptor assays in breast cancer: dextran coated charcoal and isoelectric focusing. Anticancer Res 3(4):243-246
24. Ferno M, Borg A, Sellberg G (1986) Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing. Acta Radiol Oncol 25(3):171-175
25. Burton K (1956) A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 62(2):315-323
26. Bonetti M, Bonetti M, Gelber RD (2000) A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 19(19):2595-2609
27. Baum M, Brinkley DM, Dossett JA, McPherson K, Patterson JS, Rubens RD, Smiddy FG, Stoll BA, Wilson A, Lea JC et al (1983) Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 2(8347):450 (Pubitemid 13043465)
28. Stewart HJ, Prescott R (1985) Adjuvant tamoxifen therapy and receptor levels. Lancet 1(8428):573 (Pubitemid 15134621)
29. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339(8785):71-85
30. Ferno M, Andersson C, Fallenius G, Idvall I (1996) Oestrogen receptor analysis of paraffin sections and cytosol samples of primary breast cancer in relation to outcome after adjuvant tamoxifen treatment. The South Sweden Breast Cancer Group. Acta Oncol 35(1):17-22 (Pubitemid 26084845)
31. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474-1481 (Pubitemid 29220854)
32. Rutqvist LE, Johansson H (2007) Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol 46(2):133-145 (Pubitemid 46277056)
33. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784-2795
34. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S et al (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25(25):3846-3852 (Pubitemid 47477259)
35. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20(8):1319-1329